Biofil Chemicals & Pharmaceuticals Ltd Share Price Today - Biofil Chemicals & Pharmaceuticals Ltd Stock Price Live NSE/BSE

Biofil Chemicals & Pharmaceuticals Ltd

NSE: BIOFILCHEM BSE: 524396

₹34.35

(-4.34%)

Tue, 17 Feb 2026, 08:13 pm

MTF 5xInvest in Biofil Chemicals & Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap578.21M

PE Ratio20.16

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Biofil Chemicals & Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
55.81
Net Profit
0.56
P/B
3.56
Sector P/E
39.49
P/E
120.97
EV/EBITDA
57.87
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
12.50
ROCE (Industry)
15.30
RONW (Industry)
13.47
ROE
1.12
ROCE
1.54
Debt/Equity
0.02
EPS (TTM)
1.70
Dividend Yield
0
Book Value
13.09
Interest Cover
19.50

Analysis

all

Pros

Biofil Chemicals and Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Biofil Chemicals and Pharmaceuticals is profitable, therefore cash runway is not a concern.
Biofil Chemicals and Pharmaceuticals is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (105.8%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 24.4x debt.

Cons

Unable to evaluate Biofil Chemicals and Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Biofil Chemicals and Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
High level of physical assets or inventory.
Biofil Chemicals and Pharmaceuticals is not covered by any analysts.
Biofil Chemicals and Pharmaceuticals has significant price volatility in the past 3 months.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	46.79	46.79	46.82	46.82	46.82
FII	0	0.00	0.00	0.00	0.00
DII	0.08	0.08	0.08	0.08	0.08
Public	53.13	53.13	53.10	53.10	53.10
Government	0	0	0	0	0

Technical Analysis

RSI

48.93

MACD

0.73

50 DMA

34.00

200 DMA

41.17

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	51.85	41.95	35.61	32.05	25.71	22.15	12.25
Fibonacci	41.95	38.17	35.84	32.05	28.27	25.94	22.15
Camarilla	31.98	31.07	30.17	32.05	28.35	27.45	26.54

Pivots Level: Classic

+19.80

51.85

+9.90

41.95

+3.55

35.61

32.05

Pivot Point

LTP: 34.90

-6.35

25.71

-9.90

22.15

-19.80

12.25

Moving Average

SMAEMA

Period

Value

10-EMA
36.16
20-EMA
35.65
30-EMA
35.26
50-EMA
35.27
100-EMA
36.88
200-EMA
40.80

Announcement Date	Purpose	Action
13 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results
12 Aug 2025	agm
30 Aug 2024	agm
24 Aug 2023	agm
09 Aug 2022	agm
14 Aug 2021	agm
25 Aug 2020	agm

Biofil Chemicals & Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Cipla Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Biofil Chemicals & Pharmaceuticals Ltd About

Biofil Chemicals & Pharmaceuticals is engaged in deals in manufacturing and trading of Pharmaceuticals. Further the company also deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1985

Headquarters

CEO

Ketan Shah

Employees

Contact

Website

http://www.biofilgroup.net

bcplcompliance@gmail.com; biofilchemicals@yahoo.co

Phone

91-731-2426700

Location

11/12 Sector E Sanwer Road, Sanwer Road Industrial Area, Indore, Madhya Pradesh, 452015

Year	History
1985	BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED was incorporated as a Private Limited company for manufacturing of pharmaceutical products.
1992	The company was converted into a Public Limited Company.
1993	The company came out with its first public issue to set up a unit to manufacture formulation based pharmaceutical products. The Company commenced commercial production in its existing formulation division.
2011	The registered office of the Company's Registrar and share transfer agent was shifted to Ankit Consultancy Private Ltd.

Client Name	Order Side	QTY	Avg Price	Date
JAYESH JAGDISHBHAI HAPANI	Sell	137782	61.19	18 Dec 2024
ANIL SHRIPAL MAGDUM HUF	Sell	92900	84.75	18 Sept 2024
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	192320	86.87	16 Sept 2024
QE SECURITIES LLP	Sell	117308	87.59	16 Sept 2024
QE SECURITIES LLP	Buy	116429	87.41	16 Sept 2024
RAJESH MAHENDRA RANKA	Buy	134000	89.3	16 Sept 2024
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	192320	86.77	16 Sept 2024
RAJESH MAHENDRA RANKA	Sell	134000	88.65	16 Sept 2024
ARPIT JAIN HUF	Buy	135916	77.19	13 Sept 2024
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	180742	75.76	13 Sept 2024

Biofil Chemicals & Pharmaceuticals Ltd News

Biofil Chemicals Publishes Q3 FY25 Financial Results

Biofil Chemicals and Pharmaceuticals Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025 in newspapers as per SEBI regulations.

14 Feb 2026

co actions results

Biofil Chemicals and Pharmaceuticals Pays Rs 4.24 Lakh Fine to BSE Under Protest

Biofil Chemicals and Pharmaceuticals Limited paid a fine of Rs 4,24,823.60 to BSE Limited for alleged non-compliance with Regulation 17(1)(c) of listing regulations. The company had filed waiver applications with both NSE and BSE but received fines of Rs 95,000 and Rs 2,65,000 from BSE, stating there is no material impact on its financial or operational activities.

03 Dec 2025

corporate governance

Biofil Chemicals and Pharmaceuticals Pays Rs 4.24 Lakh Fine to NSE Under Protest

Biofil Chemicals and Pharmaceuticals Limited paid a fine of Rs 4,24,823.60 to NSE after its waiver application for non-compliance under Regulation 17(1)(c) of listing regulations was rejected. The company states there is no material impact on its financial, operational or other activities from this regulatory action.

26 Nov 2025

corporate governance

Biofil Chemicals Reports Mixed Quarterly Performance with Revenue Decline but Improved Profitability

Biofil Chemicals and Pharmaceuticals Limited reported revenue from operations of Rs 199.73 lakhs for the quarter ended September 30, 2025, down from Rs 334.02 lakhs in the previous year, while achieving a net profit of Rs 241.10 lakhs compared to a loss of Rs 55.78 lakhs in the same period last year. The company's board approved the unaudited financial results for the quarter and half-year ended September 30, 2025, showing improved profitability despite lower operational revenue across its pharma and chemicals divisions.

13 Nov 2025

earnings

Biofil Chemicals Shareholders Approve Sale of Industrial Land Leasehold Rights

Biofil Chemicals and Pharmaceuticals Limited received shareholder approval through postal ballot for the sale, transfer, or disposal of leasehold rights for a vacant portion of industrial land measuring 80,156 square meters at Pithampur, Madhya Pradesh. The special resolution was passed with 99.93% votes in favor, with 8,974,224 votes supporting and 6,503 votes against. The e-voting process was conducted from August 15 to September 13, 2025, with L.N. Joshi serving as scrutinizer. Out of 25,845 total shareholders, postal ballot notices were sent to 23,017 members via email. The resolution allows the company to dispose of leasehold rights for the vacant industrial land located at Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, District Dhar, Madhya Pradesh.

15 Sept 2025

corporate action

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800